American Oriental Bioengineering, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AOBI research report →
Companywww.bioaobo.com
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting.
- CEO
- Shujun Liu
- IPO
- 2001
- Employees
- 3,719
- HQ
- Beijing, CN
Price Chart
Valuation
- Market Cap
- $88
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -1.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 30.57%
- Op Margin
- -37.89%
- Net Margin
- -41.15%
- ROE
- -16.84%
- ROIC
- -13.88%
Growth & Income
- Revenue
- $145.10M · -31.78%
- Net Income
- $-59,713,000 · 12.82%
- EPS
- $-781.24 · 13.37%
- Op Income
- $-54,972,000
- FCF YoY
- -264.46%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.22
- Avg Volume
- 462.124
Get TickerSpark's AI analysis on AOBI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AOBI Coverage
We haven't published any research on AOBI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AOBI Report →